Navigation Links
Breakthrough In Parkinson's research

The accumulation of clumps of the protein, alpha-synuclein, in the brain, in is considered to be the hallmark of Parkinson's disease// , according to Aaron Gitler, a postdoctoral scientist , at the Whitehead Institute in Cambridge, Massachusetts. He, along with fellow postdoctoral researcher, Anil Cashikar, are investigating the ways of preventing formation of these clumps, and also to understand if this might prevent the death of neurons, whose deterioration results in the symptoms of Parkinson’s disease.

They began their work with the simple yeast cells, employing an array engineered by the Harvard Institute of Proteonomics, and infected those cells with alpha-synuclein. They reasoned that if they identified genes that were expressed in a rescued cell, that would alert them about how alpha-synuclein harmed a cell.
.
Most of the genes they identified were involved in the production of cellular proteins and its folding into the appropriate shape. Working with researchers at the University of Missouri, Kansas City, they demonstrated that a mutated form of alpha-synuclein destroyed a key protein in this process, resulting in cell death.

The next step was to find a gene that could produce this key transport protein, in order to save the cells.

"We were surprised that when we tested this gene in higher animals -- fruit flies, worms, rat cells -- remarkably we could reverse Parkinson's symptoms in higher animals," Gitler said. "There are obvious implications for drug targets and the basic mechanism of how the disease occurs."

The researchers tried various methods of increasing production of the transport protein and in each case; the nerve cells were restored to health.

Their research findings appear in the June 23 issue of the journal Science.

Gitler added. "We hope that in the long run we can get a very good understanding of this and other cellular defects," he said. "Knowing these details will
'"/>




Page: 1 2

Related medicine news :

1. Sperm washing helps couples – Breakthrough in focu
2. ZD1839 Proves Effective - A Breakthrough in fighting Lung Cancer
3. Breakthrough in eye treatment
4. Genetic Breakthrough in Common Eye Problem
5. Breakthrough in cancer therapy
6. Breakthrough in Type II Diabetes
7. Breakthrough In Stem Cell Work
8. A Likely Breakthrough For Prostate Cancer Patients
9. New DNA Breakthrough Can Change Future Of Medicine
10. Breakthrough In New Vaccine For Malaria
11. Medical Breakthrough - Kidney Transplant Recipient Survives Without Drugs
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Breakthrough Parkinson research

(Date:1/7/2009)...rk for ER patients with hypoxia remains unclear , ...ing to the world,s most elevated natural laborator...hat the established medical rules about the amount...wrong. , "Some people can tolerate extremely low l...d Dr. Michael P.W. Grocott, from University Colleg...
(Date:1/7/2009)...nt Increase in Patients Unable to Pay Out-of-Pocke...iting Hospital ERs , , SACRAMENTO, Calif., Jan. 7... having a dramatic impact on California,s communit... report by the California Hospital Association (CH...onducted in November 2008 among hospital chief fin...
(Date:1/7/2009)...t failure, slowed cell growth, study says , ... a drug used for many years to treat irregular hea...-fighting agent, researchers report. , Cancer cell... many of these cells are oxygen-deprived and need ...ypoxia-inducible factor (HIF-1), which help cells ...
(Date:1/7/2009)...le at Albertsons stores throughout AR, AZ, CO, FL,...n,s LLC announced an expansion of its Albertsons ...y by introducing a new offering of $10.99 for a 90...n, Albertsons has added new generic medications to...covered by this discount program. Additional medi...
Breaking Medicine News(10 mins):Health News:Study of Everest Climbers Questions Oxygen Use 2Health News:Study of Everest Climbers Questions Oxygen Use 3Health News:Economic Downturn Takes Toll on California Hospitals 2Health News:Heart Drug May Be a Cancer Fighter 2Health News:Albertson's LLC Launches $10.99 for 90-day Supply of Generic Drugs as Part of Rx-tra Savings Prescription Discount Program 2
...cientists have reported a breakthrough, towards th...eclampsia.// The researchers from the US National...lampsia had high levels of two proteins several mo...Reporting their findings they explained that the t...
...uicide is the third leading cause of death in Cana...It is also a prevalent problem within Aboriginal c...proaching on September 10, 2006, two experts from ... are available to comment on the health challenges...
...he U.N. children's agency, UNICEF and the Barcelon... the team has agreed to donate $1.9 million a year...leged children with AIDS in developing countries. ...ds the AIDS programs in Swaziland, a poverty stric...
...hikungunya has re-emerged in the country after a p...Maharashtra, Andhra, Tamil Nadu and Kerala. Recent...hikungunya fever. Mosquitoes are the carriers who...o human. The National Institute of Communicable D...
Other Medicine News:Health News:Placental Proteins Could Be Responsible For Pre-eclampsia 2Health News:Getting Serious About Suicide Prevention 2
(Date:1/7/2009)...-- ImQuest Life Sciences announced today the succe... and Drug Administration to initiate human clinica...tor IQP-0410. ImQuest anticipates initiating their...-0410 is a novel small molecule inhibitor of HIV w...nscriptase inhibitor (NNRTI). The compound possess...
(Date:1/6/2009)...s from prior U.S., U.K. and China Trials , , SA...nc. (VTI), a development stage company targeting l...as begun for a randomized, controlled, multi-cente...acorporeal Liver Assist Device (ELAD) as a treatme...er three protocols. The study is open for enrollme...
(Date:1/6/2009)...SNewswire/ -- Sequella, Inc., a clinical-stage bio...emic potential, announced today that SQ109, its le...s (TB), was the first drug approved for evaluation...ynport Vaccine Company LLC and Quintiles Transnati...ute of Allergy and Infectious Diseases (NIAID), Na...
(Date:1/5/2009)...lene Pharmaceuticals announced today that it has i...protein kinase inhibitor, CX-4945, in patients wit...ultiple myeloma. The primary endpoints of the oral..., tolerance and PK properties of CX-4945 and to se...addition, multiple mechanism-related pharmacodynam...
Breaking Medicine Technology:ImQuest Submits Investigational New Product Application to the Food and Drug Administration to Initiate HIV Therapeutic Clinical Trials with IQP-0410 2ELAD(R) Liver Support System Study Initiated at Multiple U.S. Centers 2ELAD(R) Liver Support System Study Initiated at Multiple U.S. Centers 3Sequella Lead Drug Compound SQ109 Selected for Phase 1B Clinical Trial Program 2Sequella Lead Drug Compound SQ109 Selected for Phase 1B Clinical Trial Program 3Cylene Pharmaceuticals Initiates Phase I Trial With CX-4945 -Breakthrough First-in Class Inhibitor of CK2 2Cylene Pharmaceuticals Initiates Phase I Trial With CX-4945 -Breakthrough First-in Class Inhibitor of CK2 3National Cancer Registrars Association and IMPAC Medical Systems Announce Best Paper Award Recipients 5035 1National Cancer Registrars Association and IMPAC Medical Systems Announce Best Paper Award Recipients 5035 2National Cancer Registrars Association and IMPAC Medical Systems Announce Best Paper Award Recipients 5035 3Richard A Schatz M D Joins Cardiums Scientific Advisory Board 5032 1Richard A Schatz M D Joins Cardiums Scientific Advisory Board 5032 2Richard A Schatz M D Joins Cardiums Scientific Advisory Board 5032 3Richard A Schatz M D Joins Cardiums Scientific Advisory Board 5032 4Rutgers research partner Stemcyte Inc expands to New Jersey 18164 1Rutgers research partner Stemcyte Inc expands to New Jersey 18164 2Go Speed Racer 21 Revving up the worlds fastest nanomotors 18161 1
... Rheumatoid Factor IgM enzyme linked immunosorbent...(RF IgM). Enzyme-linked immunosorbent assay method...M Rheumatoid Factor in human serum. The results of...gnosis of Rheumatoid Arthritis when supported by o...
Rheumatoid Factor , R1: 4 X 20 ml buffer, R2: 2 X 8 ml antibody, Test / Kit: 320 (H717)
...r is a high precision optical system for corneal t...terior eye segment, based on a Revolving Dual Chan...GALILEI combines the advantages of two technologie...re data, while Scheimpflug imaging is optimal for ...
EXTEND is an absorbable synthetic punctal implant that provides occlusion up to three months. It is packaged 20 implants per box in sizes of .0.3mm, 0.4mm, 0.5mm. A variety pack in also available w
Medicine Products: